Morfelden Walldorf

Researchers are evaluating different treatment approaches for male patients with Hemophilia A who have developed inhibitors to replacement factor VIII (FVIII) therapy. This serious bleeding disorder results from a lack of FVIII, causing frequent bleeding episodes that can damage joints and tissues. The study aims to document current immune tolerance induction (ITI) methods and assess their safety and effectiveness, including treatments combining FVIII and emicizumab. Participants will be assigned to treatment groups based on their current therapy and may switch groups if their treatment changes, with a follow-up period of up to 5 years. The study includes three treatment groups: Group 1 receives ITI with FVIII products Nuwiq, octanate, or wilate, with bypassing agents aPCC or rFVIIa used as needed; Group 2 receives ITI combined with emicizumab plus aPCC or rFVIIa as needed; Group 3 receives routine prophylaxis with emicizumab, aPCC, or rFVIIa without ITI. All treatments are administered by injection, either intravenously or subcutaneously, with dosages determined by the investigators based on patients' clinical conditions. Participants will be monitored regularly over a maximum of 5 years, with researchers measuring inhibitor levels, FVIII recovery and half-life, and annual bleeding rates. The study collects data on treatment efficacy and safety, including how well inhibitors are eradicated, FVIII activity, and bleeding control. Medical history, bleeding episodes, and laboratory tests will be documented to evaluate long-term outcomes and support treatment decisions for this patient group.